# Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

> **NCT03522441** · PHASE3 · COMPLETED · sponsor: **Akorn, Inc.** · enrollment: 1125 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Clindamycin 1% Gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03522441
- **Lead sponsor:** Akorn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-27
- **Primary completion:** 2019-04-22
- **Final completion:** 2019-04-22
- **Target enrollment:** 1125 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522441, "Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03522441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*